KR102474757B1 - 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 - Google Patents

발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102474757B1
KR102474757B1 KR1020217035334A KR20217035334A KR102474757B1 KR 102474757 B1 KR102474757 B1 KR 102474757B1 KR 1020217035334 A KR1020217035334 A KR 1020217035334A KR 20217035334 A KR20217035334 A KR 20217035334A KR 102474757 B1 KR102474757 B1 KR 102474757B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
nucleotide sequence
cell
exogenous nucleic
rrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217035334A
Other languages
English (en)
Korean (ko)
Other versions
KR20210135340A (ko
Inventor
로버트 밥
다리야 부라코프
강 첸
제임스 피. 팬들
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20210135340A publication Critical patent/KR20210135340A/ko
Application granted granted Critical
Publication of KR102474757B1 publication Critical patent/KR102474757B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020217035334A 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 Active KR102474757B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662325385P 2016-04-20 2016-04-20
US62/325,385 2016-04-20
KR1020187029371A KR20180134894A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
PCT/US2017/028552 WO2017184831A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of an expression-enhancing locus

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029371A Division KR20180134894A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20210135340A KR20210135340A (ko) 2021-11-12
KR102474757B1 true KR102474757B1 (ko) 2022-12-07

Family

ID=58701850

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217035334A Active KR102474757B1 (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
KR1020187029371A Ceased KR20180134894A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187029371A Ceased KR20180134894A (ko) 2016-04-20 2017-04-20 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법

Country Status (15)

Country Link
US (2) US11530277B2 (https=)
EP (1) EP3445780A1 (https=)
JP (3) JP7134868B2 (https=)
KR (2) KR102474757B1 (https=)
CN (2) CN116004544A (https=)
AR (1) AR108295A1 (https=)
AU (2) AU2017253240B2 (https=)
BR (1) BR112018071285A2 (https=)
CA (1) CA3015371A1 (https=)
EA (1) EA201892137A1 (https=)
IL (2) IL262268B2 (https=)
MX (2) MX2018012866A (https=)
SG (2) SG11201807881VA (https=)
TW (1) TW201803981A (https=)
WO (1) WO2017184831A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018071285A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores, vetor, sistema, e, método
IL275462B2 (en) * 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
WO2020084034A1 (en) * 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
AU2019403279A1 (en) * 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
JP7250950B2 (ja) 2019-03-29 2023-04-03 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットを標的指向組込みすることによってＦｃＲｎ発現細胞を作製するための方法
JP7522100B2 (ja) 2019-04-02 2024-07-24 中外製薬株式会社 標的特異的な外来遺伝子の導入方法
EP3986924A1 (en) * 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CA3140323A1 (en) * 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
AU2020294879A1 (en) 2019-06-19 2021-12-16 F. Hoffmann-La Roche Ag Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
CN118547004A (zh) * 2019-06-19 2024-08-27 豪夫迈·罗氏有限公司 通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法
CN114008212B (zh) * 2019-06-19 2024-12-06 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生三价抗体表达细胞的方法
AU2020308002A1 (en) * 2019-06-26 2022-01-20 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
EP4087925A2 (en) * 2020-01-10 2022-11-16 F. Hoffmann-La Roche AG Method for the assembly of large nucleic acids from short fragments
TW202342755A (zh) * 2021-12-22 2023-11-01 美商建南德克公司 多載體重組酶介導的匣式交換
TW202528546A (zh) 2023-09-07 2025-07-16 美商再生元醫藥公司 經共價表面修飾之腺相關病毒的生產及純化
CN119955730A (zh) * 2023-11-08 2025-05-09 深圳太力生物技术有限责任公司 一种细胞株及其制备方法与应用
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2013190032A1 (en) 2012-06-22 2013-12-27 Lonza Biologics Plc Site-specific integration
WO2014121087A1 (en) * 2013-02-01 2014-08-07 Regeneron Pharmaceuticals, Inc. Antibodies comprising chimeric constant domains

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
EA005921B1 (ru) 2000-08-07 2005-08-25 Женсет Ген и белок, ассоциированные с шизофренией
GB0209884D0 (en) 2002-04-30 2002-06-05 Ares Trading Sa Proteins
ES2439874T3 (es) 2002-05-29 2014-01-27 Regeneron Pharmaceuticals, Inc. Sistema de expresión en eucariotas inducible
WO2004046340A2 (en) 2002-11-14 2004-06-03 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
EP2115136A4 (en) 2006-12-21 2010-05-19 Glaxosmithkline Llc NOVEL PROCEDURE
WO2008089396A1 (en) 2007-01-19 2008-07-24 Invitrogen Corporation Compositions and methods for genetic manipulation and monitoring of cell lines
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
MY192182A (en) * 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TW202423993A (zh) 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
BR112017008022A2 (pt) * 2014-10-23 2018-02-20 Regeneron Pharmaceuticals, Inc. célula, polinucleotídeo, veículo, e, métodos para modificação de um genoma de células cho e para preparação de uma proteína de interesse.
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
BR112018071285A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores, vetor, sistema, e, método

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) * 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2013190032A1 (en) 2012-06-22 2013-12-27 Lonza Biologics Plc Site-specific integration
WO2014121087A1 (en) * 2013-02-01 2014-08-07 Regeneron Pharmaceuticals, Inc. Antibodies comprising chimeric constant domains

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biotechnol Prog.,31(6):1645-1556(2015.)
Cytotechnology.,51(3):171-182(2006.7.)

Also Published As

Publication number Publication date
BR112018071285A2 (pt) 2019-02-12
US12503520B2 (en) 2025-12-23
CN109071633A (zh) 2018-12-21
SG10202010156XA (en) 2020-11-27
JP2022164824A (ja) 2022-10-27
AU2017253240B2 (en) 2024-07-04
IL309065A (en) 2024-02-01
IL262268B2 (en) 2024-05-01
EP3445780A1 (en) 2019-02-27
CA3015371A1 (en) 2017-10-26
AR108295A1 (es) 2018-08-08
JP2019514358A (ja) 2019-06-06
JP2024164196A (ja) 2024-11-26
KR20180134894A (ko) 2018-12-19
AU2024220126A1 (en) 2024-10-17
MX2024014381A (es) 2024-12-06
JP7789143B2 (ja) 2025-12-19
MX2018012866A (es) 2019-03-11
TW201803981A (zh) 2018-02-01
WO2017184831A1 (en) 2017-10-26
US11530277B2 (en) 2022-12-20
KR20210135340A (ko) 2021-11-12
US20190263937A1 (en) 2019-08-29
IL262268A (en) 2018-11-29
AU2017253240A1 (en) 2018-09-20
SG11201807881VA (en) 2018-10-30
CN109071633B (zh) 2022-11-18
EA201892137A1 (ru) 2019-03-29
JP7134868B2 (ja) 2022-09-12
CN116004544A (zh) 2023-04-25
IL262268B1 (en) 2024-01-01
US20230322956A1 (en) 2023-10-12
JP7546015B2 (ja) 2024-09-05
IL309065B1 (en) 2026-03-01

Similar Documents

Publication Publication Date Title
US12503520B2 (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
US12528883B2 (en) Compositions and methods for making antibodies based on use of expression-enhancing loci
EA051643B1 (ru) Композиции и способы получения антител, основанные на применении локуса, обеспечивающего повышенную экспрессию
EA044725B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA046654B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4